We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+12.05%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.07B
AUM Growth
-$249M
Cap. Flow
-$414M
Cap. Flow %
-13.47%
Top 10 Hldgs %
34.44%
Holding
117
New
6
Increased
34
Reduced
30
Closed
8

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$18.4M
2
ZBIO
Zenas BioPharma
ZBIO
+$15.8M
3
SMMT icon
Summit Therapeutics
SMMT
+$14.5M
4
NUVL
Nuvalent
NUVL
+$14.4M
5
CYTK icon
Cytokinetics
CYTK
+$11.5M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$168M
2
IDXX icon
Idexx Laboratories
IDXX
+$58.2M
3
EVH icon
Evolent Health
EVH
+$51.7M
4
BSX icon
Boston Scientific
BSX
+$28.2M
5
ACHC icon
Acadia Healthcare
ACHC
+$26.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.71%
2 Consumer Staples 1.99%
3 Financials 0.11%
4 Industrials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
26
Revolution Medicines
RVMD
$44.4B
$45.8M 1.49%
1,009,945
+66,750
+7% +$2.91M
MRUS
27
DELISTED
Merus
MRUS
$44.6M 1.45%
892,549
-108,524
-11% -$5.67M
NUVL
28
DELISTED
Nuvalent
NUVL
$44M 1.43%
429,994
+174,005
+68% +$14.4M
MREO
29
Mereo BioPharma
MREO
$43.5M
$39.2M 1.27%
9,534,170
+250,678
+3% +$1.04M
BSX icon
30
Boston Scientific
BSX
$73.1B
$38.5M 1.25%
460,000
-357,500
-44% -$28.2M
SRPT icon
31
Sarepta Therapeutics
SRPT
$1.81B
$38.4M 1.25%
307,500
+23,500
+8% +$3.25M
EW icon
32
Edwards Lifesciences
EW
$53B
$38.1M 1.24%
576,900
+26,900
+5% +$1.95M
CLDX icon
33
Celldex Therapeutics
CLDX
$3.37B
$37.5M 1.22%
1,103,778
-295,216
-21% -$11.2M
AGL icon
34
Agilon Health
AGL
$1.63B
$35.8M 1.16%
363,872
+7,872
+2% +$1.02M
DXCM icon
35
DexCom
DXCM
$33.1B
$35.1M 1.14%
524,000
+24,000
+5% +$1.97M
IMVT icon
36
Immunovant
IMVT
$8.24B
$34.8M 1.13%
1,221,309
+35,655
+3% +$1.05M
ZLAB icon
37
Zai Lab
ZLAB
$2.65B
$31.8M 1.03%
1,315,673
+17,800
+1% +$336K
PODD icon
38
Insulet
PODD
$9.91B
$31.2M 1.01%
134,000
-61,000
-31% -$12.5M
AGIO icon
39
Agios Pharmaceuticals
AGIO
$1.95B
$31.1M 1.01%
699,389
-344,872
-33% -$15.7M
IRTC icon
40
iRhythm Holdings
IRTC
$4.1B
$29.5M 0.96%
397,500
– –
ALGN icon
41
Align Technology
ALGN
$12.5B
$29.1M 0.95%
114,500
-13,000
-10% -$3.07M
BCRX icon
42
BioCryst Pharmaceuticals
BCRX
$2.51B
$27.5M 0.9%
3,622,358
+3,100
+0.1% +$23.6K
INSP icon
43
Inspire Medical Systems
INSP
$1.73B
$27.4M 0.89%
130,000
– –
AKRO
44
DELISTED
Akero Therapeutics
AKRO
$26.8M 0.87%
933,399
-140,862
-13% -$3.67M
AZTA icon
45
Azenta
AZTA
$1.54B
$25.8M 0.84%
532,500
-163,500
-23% -$8.5M
LEGN icon
46
Legend Biotech
LEGN
$4B
$24.8M 0.81%
508,932
+3,146
+0.6% +$168K
WRBY icon
47
Warby Parker
WRBY
$3.26B
$23.5M 0.76%
1,439,050
-640,950
-31% -$9.65M
SMMT icon
48
Summit Therapeutics
SMMT
$11.9B
$22.8M 0.74%
+1,040,000
New +$14.5M
LFST icon
49
Lifestance Health
LFST
$4.55B
$21.7M 0.71%
3,101,000
-1,726,700
-36% -$10.4M
OSCR icon
50
Oscar Health
OSCR
$8.54B
$21.5M 0.7%
1,011,400
-240,100
-19% -$4.32M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Rock Springs Capital Management held 117 positions worth $3.07B, down 7.5% from $3.32B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management withdrew a net $414M in Q3 2024, closing 8 positions and reducing 30 holdings. Its most notable exit was Idexx Laboratories, an estimated $58.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rock Springs Capital Management opened a new position in Zenas BioPharma worth $14.9M.

  • Rock Springs Capital Management's largest Q3 2024 buy was Zenas BioPharma: 878,667 shares worth $14.9M.
  • Rock Springs Capital Management added most to Eli Lilly in Q3 2024, an estimated $18.4M increase.
  • Rock Springs Capital Management's biggest Q3 2024 reduction was Blueprint Medicines, cutting an estimated $168M.
  • Rock Springs Capital Management fully exited Idexx Laboratories in Q3 2024, selling an estimated $58.2M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $3.07B portfolio in Q3 2024.
  • Rock Springs Capital Management opened 6 new positions and closed 8 in Q3 2024.
  • Rock Springs Capital Management's portfolio value fell 7.5% quarter-over-quarter to $3.07B.

Based on Rock Springs Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.